Loading
A phase 3 trial of HC-1119 in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). is a phase 3 interventional study registered as NCT03851640 by Hinova Pharmaceuticals Inc., with 417 participants planned, started 2019-04-12 and due to reach its primary completion in 2025-09. Interventions recorded: HC-1119 and placebo.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.